Since the publication of DANISH, the largest ever trial of implantable cardioverter-defibrillators (ICDs) in patients with non-ischaemic heart failure (HF), cardiologists are less certain which of their patients should receive an ICD.
Falling rates of sudden death
So why was DANISH neutral? As ICDs can only reduce sudden arrhythmic death, the observation that rates of sudden death have decreased over the last 20 years is likely to be relevant. In a recent analysis of 40 195 patients from 12 pivotal HF trials, rates of sudden cardiac death had reduced by 44% over a 20-year period (trials were conducted from the mid-90s to 2015). 7 This is almost certainly due to major advances in pharmacological therapy for HF. In the DANISH trial, rates of sudden death were low; over the 5 years of follow-up of 1116 patients, only 70 patients had a sudden death. Sudden death occurred in 24 patients (4.3%) in the ICD group and in 46 patients (8.2%) in the control group (HR 0.50; 95% CI 0.31-0.82; P = 0.005).
1 While the relative risk reduction is impressive, the absolute reduction in sudden death over a mean follow-up of more than 5 years was only 3.9%. Sudden death rates have been further reduced by sacubitril/valsartan (which was not available during the DANISH trial), so it could be argued that it is even more difficult in 2018 to reduce sudden death rates.
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Can populations that benefit from implantable cardioverterdefibrillators be identified?
As ICDs reduce sudden death it is logical to attempt to identify populations at high risk of sudden death. Perhaps ICDs should only be implanted in these groups? There are two approaches to identify subgroups at high risk of sudden death. Firstly, by identifying subgroups in previous trials that appeared to benefit and, secondly, to use risk stratification methods (for example using imaging techniques or biomarkers thought to indicate high risk).
Benefit of implantable cardioverter-defibrillators in the young
Subgroup analysis of neutral trials should always be regarded with caution but there does appear to be a subgroup that might benefit (more) from ICDs. Younger patients appear to have more to gain. In DANISH there appeared to be greater benefit of ICDs in the young compared to older patients in both continuous and categorical analyses; the younger the patient the greater the apparent benefit. aged over 70. In this analysis of DANISH, there was a hint of why there is greater benefit of ICDs in the young; sudden death was more common in younger compared to older patients. If older patients are dying of pump failure and non-cardiovascular causes it should not surprise us that mortality is not reduced by ICDs. DANISH is not alone to report a suggestion of more benefit in the young. For example, in SCD-HeFT, the HR for those <65 years of age was 0.68 (95% CI 0.50-0.93) compared to 0.86 (95% CI 0.62-1.18) for those aged over 65 (P interaction not given). 6 There are causes of non-ischaemic HF that are characterised by very high rates of ventricular arrhythmias (e.g. lamin A/C mutations). Intuitively, it seems reasonable to prioritise these patients for ICD implantation. Perhaps our increasing knowledge of subtypes of non-ischaemic HF will allow identification of other high-risk groups.
Identifying populations at high risk of sudden death
What about trying to identify a population which stands to gain from ICD therapy by using risk stratifying methods for sudden death? Microvolt T-wave alternans had its advocates previously but has not been shown to be a useful tool to select patients for ICD therapy. 10 More recently, myocardial scar (late gadolinium enhancement) detected by cardiac magnetic resonance imaging has been suggested as a means of selecting patients at high risk of sudden death who might benefit from ICDs. This technique is being prospectively tested in a randomised international trial of ICD vs. implantable loop recorder with a primary endpoint of sudden cardiac death or ventricular tachycardia leading to syncope (CMR_GUIDE, ClinicalTrials.gov ID number: NCT01918215). The investigators have chosen to study patients with ejection fractions >35% (perhaps surprisingly) of ischaemic or non-ischaemic aetiology but this tool could be used as an entry criterion in trials in patients with ejection fractions <35%. Another technique which is being tested is cardiac metaiodobenzylguanidine (MIBG) scanning. MIBG is a measure of sympathetic cardiac activity; those with greater levels of activity may be at greater risk of sudden death-and therefore be candidates for ICD therapy. ADMIRE-ICD (ClinicalTrials.gov ID number: NCT02656329) is a randomised trial of ICD vs. no ICD in 2000 patients with high cardiac MIBG activity and an ejection fraction <35% of both ischaemic and non-ischaemic aetiology. The primary endpoint is all-cause mortality.
Unclear benefit but common complications
What about complication rates of ICDs? If there is marginal or no gain to an invasive therapy, clinicians are mandated to consider any harm that a patient might be exposed to. DANISH reported a substantial complication rate. 11 If a patient is to be offered an ICD for non-ischaemic HF, he/she should certainly be informed of the cons of ICD implantation before they consent. As older patients (>70 years of age) have more complications than their younger counterparts, this is an additional reason to think carefully before recommending ICD implantation in these patients.
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Implantable cardioverter-defibrillators for heart failure secondary to coronary artery disease
The evidence for ICDs in non-ischaemic HF has thus been challenged by DANISH. What about primary prevention ICDs for those with an ejection fraction <35% secondary to coronary artery disease? For these patients the evidence that resulted in a class IA recommendation by the European Society of Cardiology HF guidelines has not changed.
2 But let's think again … SCD-HeFT 6 and MADIT II 12 are the trials that the IA recommendations are based on. Is it conceivable or likely that if these trials were repeated in the modern era that results would be different? The decline in sudden death rates is not exclusive to patients with non-ischaemic HF. 7 Medical therapy has improved for those with HF regardless of aetiology. There is a strong argument for a new primary prevention ICD trial (or trials) in patients with HF secondary to coronary artery disease on contemporary medical therapy. Will anyone be brave enough to do this? It is likely that such a trial will be undertaken in the coming years.
Cardiac resynchronisation therapy -additional value of implantable cardioverter-defibrillators?
What about cardiac resynchronisation therapy (CRT) and ICDs? Who should receive a CRT pacemaker alone (CRT-P) and who should receive a CRT defibrillator (CRT-D)? No dedicated trial has addressed this question which arises daily in cardiology units internationally. Two trials do give a glimpse of the possible additional value of CRT-P vs. CRT-D. COMPANION had a three-arm randomisation to CRT-D, CRT-P and optimal medical therapy alone.
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This trial was not powered to detect a difference between CRT-D and CRT-P and no difference was seen. Overall, 60% of patients in the DANISH trial received CRT, so to some extent this was a trial of CRT-P vs. CRT-D. The absence of effect of ICDs in DANISH was similar in those with and without CRT (HR 0.91, 95% CI 0.64-1.20, and HR 0.83, 95% CI 0.58-1.19, respectively, P interaction = 0.73).
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A dedicated stand-alone trial of CRT-P vs. CRT-D is undoubtedly necessary.
It should be noted that even with a class I indication for ICDs, number of patients receiving these devices has been relatively options for new trials to investigate the risk/benefit of implantable cardioverter-defibrillators • ICD vs. no ICD in HF secondary to DCM (no CRT in either arm) all comers (EF <35%)
• ICD vs. no ICD in HF secondary to CAD (no CRT in either arm) with low EF (EF <35%)
• ICD vs. no ICD in younger patients a with HF secondary to DCM (no CRT in either arm) with low EF (EF <35%)
• ICD vs. no ICD in older patients b with DCM (no CRT in either arm) with low EF (EF <35%)
• ICD vs. no ICD in DCM (no CRT in either arm) and low EF with high-risk markers (e.g. CMR scar or MIBG) (EF <35%)
• CRT-P vs. CRT-D in all comers (EF <35%)
• CRT-P vs. CRT-D in HF secondary to DCM with low EF (EF <35%)
• CRT-P vs. CRT-D in HF secondary to DCM with high-risk markers (e.g. CMR scar or MIBG) with low EF (EF <35%)
• CRT-P vs. CRT-D in HF secondary to CAD with low EF (EF <35%)
• CRT-P vs. CRT-D in HF secondary to CAD in younger patients a with low EF (EF <35%)
• CRT-P vs. CRT-D in HF secondary to CAD in older patients b with low EF (EF <35%)
• ICD vs. no ICD in those with EF >35% with high-risk markers (e.g. CMR scar or MIBG)
CAD, coronary artery disease; CMR, cardiac magnetic resonance; CRT, cardiac resynchronisation therapy; CRT-D, cardiac resynchronisation therapy-defibrillator; CRT-P, cardiac resynchronisation therapy-pacemaker; DCM, dilated cardiomyopathy; EF, ejection fraction; HF, heart failure; ICD, implantable cardioverter-defibrillator; MIBG, metaiodobenzylguanidine. a >65 or 70 years (or other category). b <65 or <70 years.
low (less than 10% of patients even in contemporary clinical trial cohorts 8 ). In most countries in the real world these numbers are even lower. Is this because of financial constraints or because cardiologists and their patients have not been overwhelmed by the absolute risk/benefit ratio?
More questions than answers
Other questions remain. Are the pros and cons of ICDs the same in clinical trials as in real life? Perhaps the rate of sudden death is higher in real life in patients who are not prescribed or do not tolerate high doses of pharmacological therapy for HF? Perhaps the benefits of ICDs in such patients are greater? What about secondary prevention ICDs? The trials of secondary prevention pre-date modern pharmacological therapy.
14,15 Randomised controlled trials of secondary prevention ICD vs. no ICD seem reasonable. What is the role of subcutaneous ICDs? These have potential benefits as they can be explanted relatively easily if complications arise or myocardial recovery occurs, but they do not offer the bradycardia pacing abilities of transvenous systems. If these are going to be used in patients with HF out with niche indications (for example congenital heart disease or when transvenous access is not possible), randomised trials to assess their efficacy are necessary.
. 
Conclusion -Opportunities for new trials
In summary, the DANISH trial has forced the cardiology community to stop and think about which patients should, and which should not, receive an ICD. In 2018 the unknowns outnumber the shrinking knowns. We do not know who is likely to benefit and who is likely to be harmed. Against this backdrop the logical way forward is to design new prospective randomised trials so that in 10 years we can have informed discussions with patients and their families about the pros and cons of these potentially life-saving devices ( Table 1) . New trials are preferable to relying on subgroup analysis and guesswork as to which patients should undergo ICD implantation. Unfortunately, there are hardly any trials that are currently recruiting. Opportunities abound. Conflict of interest: none declared.
